COVID-19: Russia's Health Watchdog Says Clinical Trials of Virus Vaccine Developed by Vektor to Wrap Up in September

Profile Picture

The world's First and newly registered Russian COVID-19 vaccine named Sputnik V which was developed by the Gamaleya Institute. Phase 3 of the vaccine trial, involving around 2,000 people, is currently underway.

According to the Russian Sputnik report on Friday citing Rospotrebnadzor, the Russia's consumer rights protection and human well-being watchdog, Russian Research Centre Vektor intends to complete clinical trials of its COVID-19 vaccine in September.

The watchdog also said that all the volunteers taking part in the clinical trials of the COVID-19 vaccine are feeling fine. "14 persons were vaccinated during the first phase, and 43 more during the second phase.


"Forty-three more volunteers from the placebo control group received a placebo", Rospotrebnadzor said.

Rospotrebnadzor went on to say that the volunteers only experienced sensitivity at the injection site, but other than that they did not have any side effects.

Last week, Russia registered the world’s first COVID-19 vaccine, named Sputnik V and developed by the Gamaleya Institute. The vaccine has been tested on 76 volunteers separately at two institutions — the Moscow-based Sechenov University and the Russian Defenсe Ministry's Burdenko Main Military Clinical Hospital. Phase 3 in the trial of the Russian vaccine, involving around 2,000 people, is currently underway.

Though several Western states voiced reservations about the vaccine's safety, the Russian Health Ministry underlined that Sputnik V underwent all the necessary checks and was proven to be capable of building immunity against the virus.